NCT03575052已完成3 期
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 784
- 试验地点
- 104
- 主要终点
- Treatment-emergent Adverse Events (TEAEs)
研究概览
简要总结
The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Can understand the nature of the trial and protocol requirements and provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met:
- •The subject's legally acceptable representative (LAR) (or study partner/caregiver, if local regulations allow) must provide written informed consent
- •The subject must provide written (if capable) informed assent
- •Subject requires some or complete assistance with one or more of the following:
- •Instrumental activities of daily living (communication, transportation, meal preparation, shopping, housework, managing medications, managing personal finances) OR
- •Basic activities of daily living (personal hygiene, dressing, eating, maintaining continence or transferring)
- •Meets clinical criteria for at least one of the following disorders, with or without cerebrovascular disease (CVD):
- •Parkinson's disease with or without dementia as defined by the Movement Disorder Society's Task Force
- •Dementia with Lewy bodies (DLB)
- •All-cause dementia, possible or probable Alzheimer's disease (AD)
- •Frontotemporal degeneration spectrum disorders, including possible or probable:
- •i. Behavioral variant frontotemporal dementia
- •ii. Progressive supranuclear palsy
- •iii. Corticobasal degeneration
- •e. Vascular dementia, including post-stroke dementia multi-infarct dementia and/or subcortical ischemic vascular dementia (SIVD)
- •Has a designated study partner/caregiver
- •Can come to the clinic for study visits with a study partner/caregiver
- •If the subject is female, she must not be pregnant or breastfeeding. She must also be of non-childbearing potential (defined as either surgically sterilized or at least 1 year postmenopausal) or must agree to use a clinically acceptable method of contraception or be abstinent.
- •If the subject is taking an antipsychotic medication at the time of screening, the antipsychotic medication must be discontinued 2 weeks or 5 half-lives (whichever is longer)
排除标准
- •Is in hospice, is receiving end-of-life palliative care, or is bedridden
- •Has psychotic symptoms that are primarily attributable to delirium or substance abuse (i.e., neuropsychiatric symptoms not related to neurodegenerative disease)
- •Has current evidence of an unstable neurological, cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematologic, or other medical disorder, including cancer or malignancies that, in the judgment of the Investigator, would jeopardize the safe participation of the subject in the study or significantly interfere with the conduct or interpretation of the study
- •Has a known personal or family history of long QT syndrome or family history of sudden cardiac death
- •Has a clinical significant CNS abnormality that is most likely contributing to the dementia or findings on MRI or CT including:
- •intracranial mass lesion
- •vascular malformation
- •evidence of >4 hemosiderin deposits
- •The urine drug screen result at Visit 1 (Screening) indicates the presence of amphetamine/methamphetamine, barbiturates, cocaine, or phencyclidine (PCP). Subjects who test positive for amphetamines and who have a valid prescription may be retested if they agree to abstain from the medication for the length of their participation in the study. The presence of benzodiazepines, marijuana (THC), or opiates does not necessarily exclude the subject from the study, as assessed by the Investigator in consultation with the Medical Monitor.
- •Has previously been enrolled in any prior clinical study with pimavanserin or is currently taking pimavanserinIs judged by the Investigator or the Medical Monitor to be inappropriate for the study for any reason
- •Additional inclusion/exclusion criteria apply. Patients will be evaluated at screening to ensure that all criteria for study participation are met. Patients may be excluded from the study based on these assessments (and specifically, if it is determined that their baseline health and psychiatric condition do not meet all pre-specified entry criteria).
研究组 & 干预措施
Drug - Pimavanserin
Experimental
干预措施: Pimavanserin (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Treatment-emergent Adverse Events (TEAEs)
时间窗: Treatment Period: 8 weeks
Number (%) of patients with treatment-emergent AEs
次要结局
- Change From Baseline to Week 8 in Extrapyramidal Symptom Rating Scale-Abbreviated (ESRS-A)(Treatment Period: 8 weeks)
- Change From Baseline to Week 8 in Mini-Mental State Examination (MMSE)(Treatment Period: 8 weeks)
研究者
研究点 (104)
Loading locations...
相似试验
招募中
3 期
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisNCT06068465Tasly Pharmaceutical Group Co., Ltd248
已完成
3 期
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisNCT01174004ACADIA Pharmaceuticals Inc.199
已完成
3 期
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisNCT00658567ACADIA Pharmaceuticals Inc.123
已完成
3 期
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease PsychosisParkinson's Disease PsychosisNCT00477672ACADIA Pharmaceuticals Inc.298
已完成
3 期
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant TreatmentAdjunctive Treatment of Major Depressive DisorderNCT03968159ACADIA Pharmaceuticals Inc.298